---
title: "Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252855752.md"
description: "Hinova released its 2025 semi-annual report, with revenue of 13.17 million yuan, a year-on-year increase of 11,899.08%. The net loss attributable to the parent company was 61.85 million yuan, and the net profit excluding non-recurring items was a loss of 73.01 million yuan, with basic earnings per share of -0.62 yuan. The significant revenue growth was mainly due to the launch of the new drug deuterated enzalutamide soft capsules, with sales revenue reaching 13.0688 million yuan"
datetime: "2025-08-13T11:52:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252855752.md)
  - [en](https://longbridge.com/en/news/252855752.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252855752.md)
generator: "portal-rs"
---

# Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan

According to the Zhitong Finance APP, Hinova (688302.SH) disclosed its semi-annual report for 2025, showing that the company achieved revenue of 13.17 million yuan during the reporting period, a year-on-year increase of 11,899.08%; the net loss attributable to shareholders of the listed company was 61.85 million yuan; the net profit excluding non-recurring items was a loss of 73.01 million yuan; basic earnings per share were -0.62 yuan.

During the reporting period, the company achieved significant growth in operating revenue, mainly due to the approval of its first Class 1 new drug, deuterated enzalutamide soft capsules (project number: HC-1119), for market launch on May 29, 2025, generating drug sales revenue of 13.0688 million yuan, while the operating revenue in the same period last year was only a small amount from material sales

### Related Stocks

- [688302.CN](https://longbridge.com/en/quote/688302.CN.md)

## Related News & Research

- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [BioInvent says BI-1808 posts promising activity in ongoing Phase 2a cancer trials](https://longbridge.com/en/news/296486934.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [Trump pushes for Kim Jong Un meeting this year, WSJ reports](https://longbridge.com/en/news/296278034.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**